Osgood在1960年统计文献上600例骨髓瘤病人自诊断时起的中数生存期约为7个月。自从用苯丙氨酸氮芥或环磷酰胺治疗后,中数生存期延长至约20个月。慢性白血病-骨髓瘤专题组于1968提出浆细胞瘤的疗效标准是达到下列一项或几项者:①血清骨髓瘤蛋白(M-蛋白)浓度或尿骨髓瘤蛋白排泄少于治疗前的50％;②骨髓瘤两个最大直径的乘积缩小超过50％;③有骨质愈合的X-线照片证据。 Osgood had a median survival time of approximately 7 months since the diagnosis of 600 myeloma patients in the 1960 statistical literature. Median survival increased to about 20 months since treatment with melphalan or cyclophosphamide. Chronic leukemia - myeloma panel in 1968 raised plasma cell tumor efficacy criteria is to achieve one or more of the following: ① serum myeloma protein (M-protein) or urine myeloma protein excretion less than 50% before treatment, ; ② The product of the two largest diameters of myeloma narrowed by more than 50%; ③ evidence of radiographic evidence of bone healing.